Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Operating Leases: 2022-2024

Historic Operating Leases for Janux Therapeutics (JANX) over the last 3 years, with Dec 2024 value amounting to $21.3 million.

  • Janux Therapeutics' Operating Leases fell 6.26% to $20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year decrease of 6.26%. This contributed to the annual value of $21.3 million for FY2024, which is 7.60% down from last year.
  • Janux Therapeutics' Operating Leases amounted to $21.3 million in FY2024, which was down 7.60% from $23.0 million recorded in FY2023.
  • Janux Therapeutics' 5-year Operating Leases high stood at $24.5 million for FY2022, and its period low was $21.3 million during FY2024.
  • Moreover, its 3-year median value for Operating Leases was $23.0 million (2023), whereas its average is $22.9 million.
  • Data for Janux Therapeutics' Operating Leases shows a maximum YoY declined of 7.60% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Janux Therapeutics' Operating Leases stood at $24.5 million in 2022, then dropped by 6.18% to $23.0 million in 2023, then decreased by 7.60% to $21.3 million in 2024.